ProMIS Neurosciences (PMN) vs Rein Therapeutics (RNTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
ProMIS Neurosciences (PMN) has outperformed Rein Therapeutics (RNTX) over the past year, losing 69.9% versus a loss of 77.2%. Over five years, RNTX leads with a -97.5% price change compared with -98.2% for PMN. Rein Therapeutics is the larger company by market cap ($29.1 million vs $28.4 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PMN | RNTX |
|---|---|---|
| Share price | $3.16 | $0.3369 |
| Market cap | $28.43M | $29.06M |
| 1-day change | -1.56% | -8.38% |
| YTD return | -53.73% | -70.96% |
| 1-year return | -69.90% | -77.24% |
| 5-year return | -98.24% | -97.47% |
| EPS (TTM) | $-6.50 | $-1.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | $-39.72M | $-49.87M |
| 52-week high | $27.40 | $2.10 |
| 52-week low | $2.78 | $0.284 |
| Distance from 52-week high | -88.47% | -83.96% |
| Analyst consensus | none | none |
| Avg. price target upside | +1248.42% | +1680.94% |
| Average volume | 164.88K | 586.68K |
| Shares outstanding | 9.00M | 86.27M |
| Employees | 10 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About ProMIS Neurosciences
PMN stock →ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
About Rein Therapeutics
RNTX stock →Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
PMN vs RNTX FAQ
Which is bigger, ProMIS Neurosciences or Rein Therapeutics?
Rein Therapeutics (RNTX) is larger, with a market capitalization of $29.06M compared with $28.43M for ProMIS Neurosciences (PMN).
Which stock has performed better over the past year, PMN or RNTX?
PMN returned -69.90% over the past 12 months, compared with -77.24% for RNTX (price return, excluding dividends). Past performance does not predict future results.
Are ProMIS Neurosciences and Rein Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.